HRA00130-C004

N/A

Report date: 2024/07/02 16:38:20

Base Information

Drug NameHRA00130-C004

Drug Alias NameHRA00130-C004

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload

Mechanisms of ActionDelta-like protein 3 inhibitors

TargetsDelta-like protein 3

Therapy Area/IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A